Related Experiment Video
Updated: Jun 21, 2026
09:10
Intestinal Epithelial Regeneration in Response to Ionizing Irradiation
Published on: July 27, 2022
Pathological response after chemoradiation for T3 rectal cancer.
S K Chennupati1, A Kamaya, G A Fisher
1Department of Radiation Oncology, Stanford University Medical Center, Stanford, CA, USA.
Summary
Preoperative chemoradiotherapy (CRT) for rectal adenocarcinoma shows a significant risk of residual nodal disease. Tumor response after CRT is linked to nodal response, impacting treatment outcomes.
Area of Science:
- Oncology
- Gastroenterology
- Surgical Oncology
Background:
- Locally advanced rectal adenocarcinoma requires effective treatment strategies.
- Preoperative chemoradiotherapy (CRT) is a standard treatment modality.
- Assessing the impact of CRT on nodal status is crucial for patient management.
Purpose of the Study:
- To evaluate the effect of preoperative chemoradiotherapy (CRT) on lymph node involvement in locally advanced rectal adenocarcinoma.
- To determine the relationship between primary tumor response and nodal response after CRT.
Main Methods:
- Retrospective analysis of 59 patients with locally advanced rectal adenocarcinoma (uT3N0 and uT3N1).
- Patients received preoperative chemoradiotherapy (CRT) with 5-FU or capecitabine-based chemotherapy.
- Staging included endoscopic ultrasound or CT; surgery was performed 27-112 days post-CRT.
Main Results:
- A significant proportion of patients had residual nodal disease (ypN+) after CRT (34.4% in uT3N0, 50.0% in uT3N1).
- ypN+ rates were higher in patients with ypT2-3 compared to ypT0-1 tumors (55.0% vs 11.1%, P = .003).
- For uT3N0, a longer interval (>46 days) between CRT and surgery was associated with a lower ypN+ rate (7.1% vs 55.6%, P = .01).
Conclusions:
- The risk of residual nodal disease after preoperative CRT for rectal adenocarcinoma is substantial.
- Primary tumor response (ypT stage) is a significant predictor of nodal response (ypN stage).
- Optimizing treatment timing and assessing tumor response are critical for improving outcomes in rectal cancer management.
Related Concept Videos
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...